Artiva Biotherapeutics, Inc. Common Stock (ARTV) is a publicly traded Healthcare sector company. As of May 21, 2026, ARTV trades at $7.81 with a market cap of $447.98M and a P/E ratio of -2.27. ARTV moved -8.60% today. Year to date, ARTV is +88.01%; over the trailing twelve months it is +262.96%. Its 52-week range spans $1.47 to $17.31. Analyst consensus is strong buy with an average price target of $35.00. Rallies surfaces ARTV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes ARTV SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $7.81 |
| Market Cap | $447.98M |
| P/E Ratio | -2.27 |
| EPS | $-3.43 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.31 |
| 52-Week Low | $1.47 |
| Volume | 1.93K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-83.86M |
| Gross Margin | 0.00% |
6 analysts cover ARTV: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.00.